Cell secreting fusion protein and application thereof
By designing CD16Ab-IL15 fusion protein and chimeric antigen receptor, the problem of insufficient survival and toxicity of CAR-NK cells was solved, and its proliferation and killing function was significantly improved, achieving efficient killing of tumor cells.
Patent Information
- Application Number
- CN202411282072.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-15
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-12
AI Technical Summary
CAR-NK cells have low survival rates and insufficient toxicity in the body, resulting in poor tumor treatment effects. It is difficult for the prior art to effectively enhance their proliferation and killing functions.
By designing a fusion protein CD16Ab-IL15, containing anti-CD16 antibodies and cytokine IL15, the proliferation and toxic function of CAR-NK cells is enhanced by self-secretion, and combined with chimeric antigen receptors to improve efficacy.
It significantly improves the proliferation and killing effect of CAR-NK cells, especially the long-term killing effect, simplifies the preparation process, improves cytotoxicity, and enhances the killing ability of tumor cells.
Smart Images

Figure BDA0005041954870000201 
Figure BDA0005041954870000202 
Figure BDA0005041954870000211
Abstract
Description
[0001] Citation of Related Applications
[0002] This application claims priority to Chinese Patent Application No. 202311197619.1 filed on September 15, 2023, the contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field
[0003] The present invention relates to the field of biomedicine, and in particular to a cell secreting a fusion protein and an application thereof. Background Art
[0004] Natural killer cells (NK cells) are a type of lymphocytes that have a strong killing effect on tumor cells and are MHC-independent. Their recognition of tumor cells mainly depends on the cross-regulation of their surface activating receptors and inhibitory receptors. After recognizing tumor cells, NK cells kill tumor cells through the following pathways: 1) Lysosomal degranulation containing perforin and granzyme produces cytotoxicity to tumor cells; 2) Release interferon (IFN-γ), tumor necrosis factor (TNF-α), etc. to participate in the recruitment and function of other lymphocytes, such as enhancing antigen-specific T cell responses, and regulating cross-regulatory networks with DC cells and neutrophils; 3) Through CD16A (FcγRIIIA), participate in antibody-dependent cell-mediated cytotoxicity (ADCC). IL-15 is a key cytokine that regulates the development, maturation, survival, proliferation and effector function of NK cells. The use of IL-15 signals to enhance NK cell-mediated tumor immunotherapy has been widely used.
[0005] Chimeric antigen receptor-modified NK (CAR-NK) cells can significantly improve the specificity of NK cell efficacy. CAR-NK cells are mainly composed of three functional domains, namely the extracellular domain, the transmembrane domain, and the intracellular domain. The extracellular domain is composed of antibodies responsible for recognizing and binding to antigens and a hinge region (Hinge) that acts as a connector. The transmembrane domain connects the extracellular domain of CAR to the intracellular signal transduction domain and anchors the receptor to the NK cell membrane. The intracellular domain is composed of a co-stimulatory domain and a signal transduction domain. Therefore, after reinfusion, CAR-NK cells can inhibit cancer cells through CAR-dependent and NK cell receptor-dependent pathways, thereby eliminating tumor antigen-positive cancer cells or cancer cells expressing NK cell receptor ligands. Summary of the invention
[0006] NK cell therapy is a promising area of clinical research, with good safety and preliminary efficacy for certain cancer patients. Compared with CAR-T cells, CAR-NK cells have their own unique advantages, but still face some challenges. These challenges include improving the survival rate of CAR-NK cells in vivo, enhancing CAR-NK cell cytotoxicity, etc. Therefore, the purpose of the present invention is to enhance the proliferation and cytotoxicity of CAR-NK cells by armoring autocrine CD16VHH antibodies and IL15 molecules in CAR-NK cells.
[0007] The first object of the present invention is to provide a cell comprising a fusion protein of an anti-CD16 antibody and cytokine IL15 (CD16Ab-IL15) or a nucleic acid encoding the fusion protein, wherein the fusion protein CD16Ab-IL15 can be secreted by the cell.
[0008] The second object of the present invention is to provide a fusion protein CD16Ab-IL15 comprising an anti-CD16 antibody and cytokine IL15.
[0009] The third object of the present invention is to provide a fusion protein, which includes the aforementioned fusion protein CD16Ab-IL15 containing anti-CD16 antibody and cytokine IL15 and a chimeric antigen receptor, and also provides a cell expressing the fusion protein.
[0010] The fourth object of the present invention is to provide a nucleic acid encoding the aforementioned fusion protein.
[0011] The fifth object of the present invention is to provide a pharmaceutical composition, which comprises the aforementioned cell or fusion protein.
[0012] In order to solve the above technical problems, the present invention includes the following technical solutions:
[0013] In one aspect, the present invention provides a cell, wherein the cell comprises a fusion protein or a nucleic acid encoding the fusion protein, wherein the fusion protein comprises a CD16 antibody and a cytokine IL15.
[0014] In some specific embodiments, the fusion protein is secreted by the cell.
[0015] In some specific embodiments, the CD16 antibody and the cytokine IL15 in the fusion protein are sequentially connected via a connecting peptide 2.
[0016] In some specific embodiments, the connecting peptide 2 comprises the amino acid sequence shown in SEQ ID NO:28.
[0017] In some specific embodiments, the CD16 antibody is Fab, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody or nanobody;
[0018] Preferably, the Nanobody is a VHH.
[0019] In some specific embodiments, the CD16 antibody is loaded monovalently or bivalently.
[0020] In some specific embodiments, the CD16 antibody comprises all three complementarity determining regions (CDRs) of the amino acid sequence shown in SEQ ID NO: 14, and the CDR regions are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system.
[0021] In some specific embodiments, the three CDRs of the CD16 antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 15, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 17, and the three CDRs are determined using the IMGT numbering system.
[0022] The CD16 antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0023] In some preferred embodiments, the CD16 antibody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0024] In some more preferred embodiments, the CD16 antibody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0025] In some preferred embodiments, the CD16 antibody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0026] In some more preferred embodiments, the CD16 antibody comprises the amino acid sequence shown in SEQ ID NO:14.
[0027] In some specific embodiments, the cytokine IL15 is wild-type IL15 or a mutant thereof;
[0028] In some preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0029] In some more preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0030] In some more preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0031] In some preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0032] In some more preferred embodiments, the cytokine IL15 comprises the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26.
[0033] In some specific embodiments, the fusion protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0034] In some preferred embodiments, the fusion protein comprises an amino acid sequence having at least 95% identity to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0035] In some more preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0036] In some preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0037] In some more preferred embodiments, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30.
[0038] In some specific embodiments, the cell is an immune effector cell,
[0039] Preferably, the immune effector cells are selected from NK cells (natural killer cells), NKT cells (natural killer T cells), T cells, monocytes, macrophages, dendritic cells or mast cells;
[0040] Preferably, the immune effector cells are NK cells;
[0041] Preferably, the immune effector cells are autologous immune effector cells or allogeneic immune effector cells.
[0042] In another aspect, the present invention provides a fusion protein.
[0043] In some specific embodiments, the fusion protein is a fusion protein comprising a CD16 antibody and a cytokine IL15.
[0044] In some specific embodiments, the fusion protein is secreted by the cell.
[0045] In some specific embodiments, the CD16 antibody and the cytokine IL15 in the fusion protein are sequentially connected via a connecting peptide 2.
[0046] In some specific embodiments, the connecting peptide 2 comprises the amino acid sequence shown in SEQ ID NO:28.
[0047] In some specific embodiments, the CD16 antibody is Fab, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody or nanobody;
[0048] Preferably, the Nanobody is a VHH.
[0049] In some specific embodiments, the CD16 antibody is loaded monovalently or bivalently.
[0050] In some specific embodiments, the CD16 antibody comprises all three complementarity determining regions (CDRs) of the amino acid sequence shown in SEQ ID NO: 14, and the CDR regions are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system.
[0051] In some specific embodiments, the three CDRs of the CD16 antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 15, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 17, and the three CDRs are determined using the IMGT numbering system.
[0052] The CD16 antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0053] In some preferred embodiments, the CD16 antibody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0054] In some more preferred embodiments, the CD16 antibody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0055] In some preferred embodiments, the CD16 antibody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 14;
[0056] In some more preferred embodiments, the CD16 antibody comprises the amino acid sequence shown in SEQ ID NO:14.
[0057] In some specific embodiments, the cytokine IL15 is wild-type IL15 or a mutant thereof;
[0058] In some preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0059] In some more preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0060] In some more preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0061] In some preferred embodiments, the cytokine IL15 comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26;
[0062] In some more preferred embodiments, the cytokine IL15 comprises the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26.
[0063] In some specific embodiments, the fusion protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0064] In some preferred embodiments, the fusion protein comprises an amino acid sequence having at least 95% identity to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0065] In some more preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0066] In some preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30;
[0067] In some more preferred embodiments, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30.
[0068] In some specific embodiments, the fusion protein further comprises a chimeric antigen receptor.
[0069] In some specific embodiments, in the fusion protein, the aforementioned fusion protein comprising CD16 antibody and cytokine IL15 is connected to the chimeric antigen receptor via a self-cleaving peptide.
[0070] In some specific embodiments, the self-cleaving peptide is P2A or T2A,
[0071] Preferably, the self-cleaving peptide P2A comprises the amino acid sequence shown in SEQ ID NO: 23, and / or
[0072] The self-cleaving peptide T2A comprises the amino acid sequence shown in SEQ ID NO:24.
[0073] In some specific embodiments, the chimeric antigen receptor is capable of binding to one or more tumor-associated antigens.
[0074] In some specific embodiments, the tumor-associated antigens include CD19, CD22, CD33, CD70, DLL3, MSLN, EGFR, HER2, EPCAM, IL13Rα2, EphA2, PSMA, MAGE, MUC16, Claudin6, Claudin18.2, SSTR2, BCMA and / or GPRC5D.
[0075] In some specific embodiments, the chimeric antigen receptor comprises a tumor-associated antigen binding molecule;
[0076] Preferably, the tumor-associated antigen binding molecule comprises a nanobody or a scFv.
[0077] In some specific embodiments, the chimeric antigen receptor further comprises a signal peptide, a transmembrane region, a hinge region, an intracellular region, a signal domain, and a connecting peptide;
[0078] Preferably, the signal peptide includes CD8α, GM-CSF signal peptide;
[0079] The connecting peptide includes connecting peptide 1;
[0080] The transmembrane region includes CD3, CD8, CD8α, CD28, NKG2D, or 2B4 transmembrane region;
[0081] The hinge region includes a CD8 hinge region, a CD8α hinge region or a CD28 hinge region;
[0082] The intracellular region includes CD28, ICOS, 4-1BB, OX40, CD27, or 2B4 intracellular region;
[0083] The signaling domain comprises a CD3ζ signaling domain;
[0084] More preferably, the chimeric antigen receptor comprises:
[0085] CD8α signal peptide;
[0086] Connector peptide 1;
[0087] NKG2D transmembrane region or CD8α transmembrane region;
[0088] CD8 hinge region or CD8α hinge region;
[0089] 2B4 intracellular region or CD28 intracellular region;
[0090] CD3ζ signaling domain;
[0091] or a combination thereof.
[0092] In a specific embodiment,
[0093] The CD8α signal peptide comprises the amino acid sequence shown in SEQ ID NO: 18;
[0094] The connecting peptide 1 comprises the amino acid sequence shown in SEQ ID NO: 27;
[0095] The NKG2D transmembrane region comprises the amino acid sequence shown in SEQ ID NO: 20;
[0096] The CD8α transmembrane region comprises the amino acid sequence shown in SEQ ID NO:34;
[0097] The CD8 hinge region comprises the amino acid sequence shown in SEQ ID NO: 19;
[0098] The CD8α hinge region comprises the amino acid sequence shown in SEQ ID NO: 33;
[0099] The 2B4 intracellular region comprises the amino acid sequence shown in SEQ ID NO: 21;
[0100] The CD28 intracellular region comprises the amino acid sequence shown in SEQ ID NO:35;
[0101] The CD3ζ signaling domain comprises the amino acid sequence shown in SEQ ID NO:22.
[0102] In some specific embodiments, the tumor-associated antigen is BCMA, GPRC5D, and / or CD19.
[0103] In some specific embodiments, the tumor-associated antigen binding molecule includes anti-BCMA nanobody, anti-GPRC5D nanobody, and / or anti-CD19 single-chain antibody.
[0104] In some specific embodiments, the anti-BCMA Nanobody comprises all three CDRs of the amino acid sequence shown in SEQ ID NO: 2, and the CDRs are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system.
[0105] In some specific embodiments, the anti-GPRC5D Nanobody comprises all three CDRs of the amino acid sequence shown in SEQ ID NO: 10, and the CDRs are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system.
[0106] In some specific embodiments, the anti-CD19 single-chain antibody comprises a heavy chain variable region VH and a light chain variable region VL; the anti-CD19 single-chain antibody comprises all six CDRs of the amino acid sequence shown in SEQ ID NO:39.
[0107] In some specific embodiments, the three CDRs of the anti-BCMA nanobody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO:6, CDR2 comprising the amino acid sequence shown in SEQ ID NO:7, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:8, and the three CDRs are determined using the Kabat numbering system.
[0108] In some specific embodiments, the three CDRs of the anti-GPRC5D nanobody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 11, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 12, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 13, and the three CDRs are determined using the IMGT numbering system.
[0109] In some specific embodiments, the three CDRs on the VH of the anti-CD19 single-chain antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO:40, CDR2 comprising the amino acid sequence shown in SEQ ID NO:41, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:42; the three CDRs on the VL of the anti-CD19 single-chain antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO:43, CDR2 comprising the amino acid sequence shown in SEQ ID NO:44, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:45; the six CDRs are determined using the Kabat numbering system.
[0110] In some specific embodiments, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 2;
[0111] In some preferred embodiments, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 2;
[0112] In some more preferred embodiments, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 2;
[0113] In some preferred embodiments, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 2;
[0114] In some more preferred embodiments, the anti-BCMA nanobody comprises the amino acid sequence shown in SEQ ID NO:2.
[0115] In some specific embodiments, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 10;
[0116] In some preferred embodiments, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 10;
[0117] In some more preferred embodiments, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 10;
[0118] In some preferred embodiments, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 10;
[0119] In some more preferred embodiments, the anti-GPRC5D Nanobody comprises the amino acid sequence shown in SEQ ID NO:10.
[0120] In some specific embodiments, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:39;
[0121] In some preferred embodiments, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 39;
[0122] In some more preferred embodiments, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 39;
[0123] In some preferred embodiments, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:39;
[0124] In some more preferred embodiments, the anti-CD19 single-chain antibody comprises the amino acid sequence shown in SEQ ID NO:39.
[0125] In some specific embodiments, the fusion protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38;
[0126] In some preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38;
[0127] In some more preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38;
[0128] In some preferred embodiments, the fusion protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38;
[0129] In some more preferred embodiments, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38.
[0130] In a specific embodiment, the fusion protein can be secreted or expressed by the cells described herein.
[0131] In another aspect, the present invention provides a nucleic acid encoding the fusion protein described herein.
[0132] In a specific embodiment, the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid;
[0133] Preferably, the nucleic acid comprises a linear nucleic acid or a circular nucleic acid;
[0134] Preferably, the nucleic acid includes DNA and RNA;
[0135] Preferably, the RNA is self-replicating or non-self-replicating.
[0136] In another aspect, the present invention provides a cell expressing the fusion protein described herein or the nucleic acid described herein.
[0137] In another aspect, the present invention provides a pharmaceutical composition comprising the cell, or fusion protein, or nucleic acid described herein.
[0138] In a specific embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0139] In another aspect, the present invention provides a use of a cell, fusion protein, nucleic acid, or pharmaceutical composition described herein for treating a tumor in a subject in need thereof;
[0140] Preferably, the treatment comprises administering to the subject an effective amount of the cells.
[0141] In another aspect, the present invention provides a use of a cell, a fusion protein, a nucleic acid, or a pharmaceutical composition described herein for preparing a medicament for treating a tumor in a subject in need thereof.
[0142] In some specific embodiments, the tumor includes tumors with high expression of tumor-associated antigens such as CD19, CD22, CD33, CD70, DLL3, MSLN, EGFR, HER2, EPCAM, IL13Rα2, EphA2, PSMA, MAGE, MUC16, Claudin6, Claudin18.2, SSTR2, BCMA and / or GPRC5D.
[0143] In some preferred embodiments, the tumor includes a tumor with high expression of BCMA, GPRC5D, and / or CD19.
[0144] In some specific embodiments, the tumor comprises a hematological tumor or a solid tumor.
[0145] In some specific embodiments, the tumor comprises a lymphoma or a leukemia, which can be selected from B-cell lymphoma, non-Hodgkin's lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma, precursor B-cell acute lymphoblastic leukemia (pre-B ALL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, hairy cell leukemia, prolymphocytic leukemia, plasmacytoma, Waldenstrom's tumor or multiple myeloma.
[0146] In some specific embodiments, the tumor includes lung cancer, breast cancer, neuroblastoma, glioma, liver cancer, gastric cancer, prostate cancer, ovarian cancer, colon cancer, rectal cancer, esophageal cancer, epithelioid pleural mesothelioma, pancreatic cancer, ovarian serous carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, bile duct cancer, endometrial cancer, etc.
[0147] Beneficial effects:
[0148] Compared with the prior art, the technical solution of the present invention has at least one of the following beneficial effects:
[0149] 1. The enhanced CAR-NK cells disclosed herein (which simultaneously secrete antibodies targeting CD16A and IL15 molecules) can improve at least one of the performance of chimeric antigen receptor proliferation or activation degree or killing effect (especially long-term killing effect) compared with CAR-NK cells.
[0150] 2. The preparation process of the enhanced chimeric antigen receptor disclosed in the present invention is simple, and does not require in vitro preparation of CD16A-targeting antibodies and IL15. In addition, the autocrine CD16A-targeting antibodies and IL15 can improve the proliferation ability and activation degree of CAR-NK cells, thereby enhancing the cytotoxicity of CAR-NK cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0151] Figure 1 Schematic diagram of the fusion protein BC structure formed by the dual-target chimeric antigen receptor targeting BCMA and GPRC5D;
[0152] Figure 2A -B control-IL15 molecule and BC-1 virus infection efficiency and MFI statistical results of NK cells;
[0153] Figure 3 The results of multiple rounds of killing experiments of control-IL15 molecules and BC-1 on NCI H929 cells;
[0154] Figure 4 control-IL15 molecule, BC-1 virus titer detection;
[0155] Figure 5 control-IL15 molecule, BC-1 positive rate detection;
[0156] Figure 6 control-IL15 molecule, BC-1 cell proliferation fold statistics;
[0157] Figures 7A-7D control-IL15 molecule, BC-1 cell surface marker detection;
[0158] Figure 8 The results of multiple rounds of killing experiments of control-IL15 molecules and BC-1 on NCI H929 cells;
[0159] Figures 9A-9B Control-IL15 molecule, short-term killing effect of BC-1 cells on NCI H929 cells and Molp8 cells;
[0160] Figure 10 RTCA detection of control-IL15 molecules, results of multiple rounds of killing experiments of BC-1 against CHOK1-hBCMA, CHOK1-hGPRC5D and mixed cells of CHOK1-hBCMA and CHOK1-hGPRC5D (1:1 mixture);
[0161] Fig.11 IFN-γ secretion detection experimental results.
[0162] Fig.12 Schematic diagram of the CAR-NK plasmid structure containing different CD19 CAR elements.
[0163] Fig.13 The results of in vitro expansion of NK cells transfected with different CD19 CAR structures or untransfected NK cells (PBNK).
[0164] Fig.14 These are the FACS test results of the CAR transfection efficiency (%) of NK cells and PBNK cells with different CD19 CAR structures.
[0165] Fig.15 These are the FACS detection results of MFI of CAR transfection of NK cells and PBNK cells with different CD19 CAR structures.
[0166] Fig.16 The killing effect of CD19 CAR-NK cells on Nalm6-luc cells for 4 hours; the effector-target ratio (E:T) was 1:2, 1:4, 1:8 and 1:16, respectively.
[0167] Fig.17 This is a multiple round of continuous killing effect of CD19 CAR-NK cells on Nalm6-luc cells; E:T=1:3.
[0168] Definitions and explanations of terms
[0169] Unless otherwise defined herein, scientific and technical terms related to the present invention shall have the meanings understood by those of ordinary skill in the art.
[0170] Furthermore, unless otherwise indicated herein, singular terms shall include pluralities and plural terms shall include the singular. More specifically, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless expressly indicated otherwise.
[0171] It should be understood that all numerical values described herein (e.g., pH, temperature, time, concentration, quantity and molecular weight, including ranges) include normal variations in measured values encountered by those of ordinary skill in the art. Thus, the numerical values described include variations of + / -0.1% to 10%, for example, + / -0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%. It should be understood that, although not always explicitly stated, all numerical designations may be preceded by the term "about". Thus, the term approximately includes variations of + / -0.1% to 10%, for example, + / -0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10%. It should also be understood that, although not always explicitly stated, the agents described herein are exemplary only, and their equivalents are known in the art.
[0172] As will be appreciated by those skilled in the art, for any and all purposes, particularly in providing a written description, all ranges disclosed include the endpoints of the range, and include all values between the endpoints of the range. All ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily considered to be fully described, and the same range can be decomposed into at least equal half, two-thirds, one-quarter, one-fifth, a few tenths, etc. As a non-limiting example, each range discussed herein can be easily decomposed into a lower third, a middle third, and an upper third, etc. As will be appreciated by those skilled in the art, all languages, such as "at most", "at least", etc., include the listed numerical values, and refer to the scope that can be subsequently subdivided into subranges as described above. Finally, as will be appreciated by those skilled in the art, ranges include each individual member.
[0173] The terms "a" and "an" herein refer to one or more than one (i.e., at least one) of the grammatical object of the article. The terms "a" or "an" when used in conjunction with "comprising" herein may mean "one", but are also consistent with the meanings of "one or more", "at least one", and "one or more than one".
[0174] The terms "include", "comprising" and "having" are used interchangeably herein and are intended to indicate the inclusiveness of the solution, meaning that the solution may have other elements in addition to the listed elements. At the same time, it should be understood that the use of "include", "comprising" and "having" descriptions herein also provides a "consisting of..." solution.
[0175] The term "and / or" as used herein includes the meanings of "and", "or" and "all or any other combination of elements linked by the corresponding term".
[0176] The terms "about" and "approximately" herein generally indicate an acceptable degree of error for a measured amount, taking into account the nature or precision of the measurement. Exemplary degrees of error are within 20%, typically within 10%, and more typically within 5% of a given numerical range. The term "substantially" means greater than 60%, more preferably greater than 80%, and most preferably greater than 90% or 95%.
[0177] The term "nucleic acid" is used in the broadest sense herein to include any compound and / or substance comprising a polymer comprising nucleotides. Each nucleotide is composed of a base, particularly a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose) and a phosphate group. Typically, nucleic acid molecules are described by a sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule. The sequence of bases is typically expressed as 5' to 3'. In this article, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, for example, complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), particularly messenger RNA (mRNA), synthetic forms of DNA or RNA, and polymers comprising a mixture of two or more of these molecules. Nucleic acid molecules can be linear or cyclic. In addition, the term nucleic acid molecule includes both sense and antisense strands, as well as single-stranded and double-stranded forms. Moreover, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derived sugar or phosphate backbone bonds or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules that are suitable as vectors for direct expression of the antibodies of the invention in vitro and / or in vivo, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA may be chemically modified to enhance the stability of the RNA vector and / or the expression of the encoded molecule, so that the mRNA may be injected into a subject to produce antibodies in vivo (see, e.g., Stadler, CR, - Mahmud, H., Celik, L., Hebich, B., Roth, AS, Roth, RP, ... & Sahin, U. (2017). Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nature medicine, 23(7), 815-817. or EP2101823B1).
[0178] Nucleic acids (also referred to as polynucleotides) may be or may include, for example, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), threose nucleic acids (TNA), glycol nucleic acids (GNA), peptide nucleic acids (PNA), locked nucleic acids (LNA, including LNA with a β-D-ribose configuration, α-LNA with an α-L-ribose configuration (diastereomers of LNA), 2′-amino-LNA with 2′-amino functionalization, and 2′-amino-α-LNA with 2′-amino functionalization), ethylene nucleic acids (ENA), cyclohexenyl nucleic acids (CeNA), or chimeras or combinations thereof. The nucleic acids described herein may be in the form of DNA molecules, RNA molecules, PNA molecules, or LNA. They may exist in single-stranded or double-stranded forms and may be linear or circular. The forms of DNA include cDNA, genomic DNA, or artificially synthesized DNA. The DNA may be single-stranded or double-stranded. The DNA may be a coding strand or a non-coding strand. The terms "nucleic acid," "nucleic acid sequence," "nucleotide sequence," or "polynucleotide" are used interchangeably herein.
[0179] The term "amino acid" herein encompasses all molecules that contain an amino functional group and an acid functional group and can be included in a polymer formed by naturally occurring amino acids, including natural molecules or synthetic molecules. Exemplarily, it includes naturally occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs with variant side chains; and all stereoisomers of any of the aforementioned amino acids, including D- and L-optical isomers and peptidomimetics.
[0180] The terms "protein", "polypeptide" and "peptide" are used interchangeably herein to refer to polymers of any length formed by peptide bonds of any amino acid, regardless of length or co-translational or post-translational modification. The polymer may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. The term also includes amino acid polymers modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as coupling with a labeling component. The polypeptide may be isolated from a natural source, may be produced by a prokaryotic or eukaryotic host using recombinant technology, or may be the product of a synthetic process.
[0181] The term "antigen binding molecule" is used in the broadest sense herein to refer to a molecule that specifically binds to an antigen. Exemplarily, antigen binding molecules include, but are not limited to, antibodies or antibody mimetics.
[0182] The term "antibody" or "antibody molecule" is used in the broadest sense herein and refers to a protein, such as an immunoglobulin chain or fragment thereof, comprising at least one immunoglobulin variable domain sequence. Antibody molecules include antibodies (e.g., full-length antibodies) and antibody fragments. "Antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen binding portion thereof. Each heavy chain consists of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains, CH1, CH2, and CH3. Each light chain consists of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region consists of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), which are interspersed in more conserved regions known as framework regions (FRs). Each VH and VL consists of three CDRs and four FRs, which are arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that can interact with antigens. The constant region of an antibody can mediate the binding of immunoglobulins to host tissues or factors, which include various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. Due to the different amino acid compositions and arrangement sequences of the constant regions of the heavy chains of immunoglobulins, their antigenicity is also different. Accordingly, the "immunoglobulins" herein can be divided into five categories, or isotypes of immunoglobulins, namely, IgM, IgD, IgG, IgA, and IgE, and their corresponding heavy chains are μ chain, δ chain, γ chain, α chain, and ε chain, respectively. The same class of Ig can be divided into different subclasses according to the difference in the amino acid composition of the hinge region and the number and position of the disulfide bonds of the heavy chain. For example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4, and IgA can be divided into IgA1 and IgA2. The light chain is divided into κ chain or λ chain according to the difference in the constant region. Each of the five classes of Ig can have κ chain or λ chain.
[0183] The term "antibody" herein also includes antibodies that do not contain light chains, for example, heavy-chain antibodies (HCAbs) produced by camelids such as dromedary camels, Bactrianus camels, Lama glama, Lama guanicoe and Vicugna pacos, and immunoglobulin new antigen receptors (Ig new antigen receptor, IgNAR) found in cartilaginous fish such as sharks.
[0184] The term "antibody" herein may be derived from any animal, including but not limited to humans and non-human animals, which may be selected from primates, mammals, rodents and vertebrates, such as camelids, llamas, ostriches, alpacas, sheep, rabbits, mice, rats or cartilaginous fish (e.g. sharks).
[0185] The term "antibody mimetic" herein refers to an organic compound or binding domain that can specifically bind to an antigen but is unrelated to the antibody structure. Exemplarily, antibody mimetic includes but is not limited to affibody, affitin, affilin, designed ankyrin repeat protein (DARPin), nucleic acid aptamer or Kunitz-type domain peptide.
[0186] The term "heavy chain antibody" herein refers to an antibody lacking the light chain of a conventional antibody. The term specifically includes, but is not limited to, a homodimeric antibody comprising a VH antigen binding domain and CH2 and CH3 constant domains in the absence of a CH1 domain.
[0187] The term "single-domain antibodies (sdAbs)" in this article is also called nanobody (Nb). It is the variable region domain of heavy chain antibodies. Its structure affects the binding of antibody VH and VL. Heavy chain antibodies are widely present in the serum of camelids and elasmobranchs. Single-domain antibodies contain only the smallest unit antigen-binding fragment of a single domain, usually composed of only 110-130 amino acids, with a molecular weight of only 12-15kDa, which is much smaller than traditional complete antibodies (150-160kDa) and their Fab fragments (about 50kDa), but they can have similar or higher specific antigen affinity than traditional antibodies. Single-domain antibodies from camelids are also called VHH (variable domain of heavy chain of heavy-chain antibody), and single-domain antibodies from elasmobranchs are also called VNAR (variable NAR).
[0188] For further description of “heavy chain antibodies” and “single domain antibodies”, “VHH domains” and “nanoantibodies”, see: Hamers-Casterman et al., Nature. 363, 446-8 (1993). Naturally occurring antibodies devoid of light chains.; Muyldermans' review article (J Biotechnol. 2001 Jun; 74 (4): 277-302. Single domain camel antibodies: current status); and the following patent applications, which are mentioned as general background art: WO 94 / 04678, WO 95 / 04079 and WO 96 / 34103; WO 94 / 25591, WO 99 / 37681, WO 00 / 40968, WO 00 / 43507, WO 00 / 65057, WO 01 / 40310, WO 01 / 44301, EP 1134231 and WO02 / 48193; WO97 / 49805, WO 01 / 21817, WO 03 / 035694, WO 03 / 054016 and WO 03 / 055527; WO03 / 050531; WO 01 / 90190; WO03 / 025020; and WO 04 / 041867, WO 04 / 041862, WO 04 / 041865, WO 04 / 041863, WO 04 / 062551, WO 05 / 044858, WO 06 / 40153, WO 06 / 079372, WO 06 / 122786, WO 06 / 122787 and WO 06 / 122825 and other prior art mentioned in these applications.
[0189] The term "multi-specificity" herein refers to the ability of an antibody or antigen-binding fragment to bind, for example, at least two different epitopes on different antigens or the same antigen. Therefore, terms such as "bispecific", "trispecific", "tetraspecific" and the like refer to the number of different epitopes that an antibody can bind. For example, conventional monospecific IgG type antibodies have two identical antigen binding sites (paratopes), so they can only bind to the same epitope (rather than binding to different epitopes). In contrast, multispecific antibodies have at least two different types of paratopes / binding sites, so they can bind to at least two different epitopes. As described herein, "complementarity determining region" refers to the antigen binding site of an antibody. In addition, a single "specificity" can refer to one, two, three or more than three identical complementary determining regions in a single antibody (the actual number of complementary determining regions / binding sites in a single antibody molecule is referred to as "valence"). For example, a single natural IgG antibody is monospecific and bivalent because it has two identical paratopes. Accordingly, a multispecific antibody comprises at least two (different) complementary determining regions / binding sites. Therefore, the term "multispecific antibody" refers to an antibody having more than one paratope and having the ability to bind to two or more different epitopes. The term "multispecific antibody" particularly includes bispecific antibodies as defined above, but also generally includes proteins, e.g. antibodies that specifically bind three or more different epitopes, scaffolds, ie antibodies with three or more paratopes / binding sites.
[0190] The term "valent" herein refers to the presence of a specified number of binding sites in an antibody / antigen binding molecule. Thus, the terms "monovalent", "divalent", "tetravalent" and "hexavalent" refer to the presence of one binding site, two binding sites, four binding sites and six binding sites in an antibody / antigen binding molecule, respectively.
[0191] "Full length antibody," "intact antibody" and "intact antibody" are used interchangeably herein and refer to antibodies having a structure substantially similar to that of a native antibody.
[0192] "Antigen binding fragment" and "antibody fragment" are used interchangeably herein, and they do not have the entire structure of a complete antibody, but only contain a part or a partial variant of a complete antibody, and the part or a partial variant has the ability to bind to an antigen. Exemplarily, "antigen binding fragment" or "antibody fragment" herein include, but are not limited to, Fab, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody, and single domain antibody.
[0193] The term "humanized antibody" herein refers to a non-human antibody that has been genetically engineered, and its amino acid sequence has been modified to increase the homology with the sequence of a human antibody. Generally speaking, all or part of the CDR region of a humanized antibody comes from a non-human antibody (donor antibody), and all or part of the non-CDR region (e.g., variable region FR and / or constant region) comes from a human immunoglobulin (recipient antibody). Humanized antibodies generally retain or partially retain the expected properties of the donor antibody, including but not limited to, antigen specificity, affinity, reactivity, the ability to increase immune cell activity or the ability to enhance immune response, etc.
[0194] The term "variable region" herein refers to the region of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen, and "heavy chain variable region" is used interchangeably with "VH" and "HCVR", and "light chain variable region" is used interchangeably with "VL" and "LCVR". The variable domains of the heavy and light chains of natural antibodies generally have similar structures, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR). A single VH or VL domain may be sufficient to confer antigen binding specificity.
[0195] The term "complementarity determining region" is used interchangeably with "CDR" herein, and generally refers to the hypervariable region (HVR) found in both the light chain and heavy chain variable domains. The more highly conserved portion of the variable domain is called the framework region (FR). As understood in the art, the amino acid position representing the hypervariable region of an antibody can vary according to the context and various definitions known in the art. Some positions within the variable domain can be considered as hybrid hypervariable positions, because these positions can be considered to be within the hypervariable region under a set of standards (such as IMGT or KABAT), and are considered to be outside the hypervariable region under different sets of standards (such as KABAT or IMGT). One or more of these positions can also be found in an extended hypervariable region. The present invention includes antibodies comprising modifications in these hybrid hypervariable positions. The heavy chain variable region CDR can be abbreviated as HCDR, and the light chain variable region can be abbreviated as LCDR. The variable domains of the native heavy and light chains each include four framework regions that mainly adopt a sheet configuration, which are connected by three CDRs (CDR1, CDR2 and CDR3), which form a loop connecting the sheet structure, and in some cases form a part of the sheet structure. The CDRs in each chain are held together in close proximity by the FR regions in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, and together with the CDRs from other antibody chains contribute to the formation of the antibody antigen binding site.
[0196] For further description of CDR, refer to Kabat, E.A., Wu, T.T., & Bilofsky, H. (1977). Unusual distributions of amino acids in complementarity determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody-combining sites. Journal of Biological Chemistry, 252(19), 6609-6616.; Kabat et al., US Department of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia, C., & Lesk, A.M. (1987). Canonical structures for the hypervariable regions of immunoglobulins. Journal of molecular biology, 196(4), 901-917.; Al-Lazikani, B., Lesk, A.M., & Chothia, C. (1997). Standard conformations for the canonical structures of immunoglobulins. Journal of molecular biology, 273(4), 927-948.; MacCallum, R.M., Martin, A.C., & Thornton, J.M. (1996). Antibody-antigen interactions: contact analysis and binding site topography. Journal of molecular biology, 262(5), 732-745.; Abhinandan, K.R., & Martin, A.C. (2008). Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains.Molecular immunology, 45(14),3832-3839.;Lefranc,MP,Pommié,C.,Ruiz,M.,Giudicelli,V.,Foulquier,E.,Truong,L.,...&Lefranc,G.(2003).IMGTunique numbering for immunoglobulin and T cell receptor variabledomains andIg superfamily V-like domains.Developmental&Comparative Immunology,27(1),55-77.; and Honegger,A.,&. A. (2001). Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. Journal of molecular biology, 309 (3), 657-670.. "CDR" herein can be annotated and defined by methods known in the art, including but not limited to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system, and the tool websites used include but are not limited to the AbRSA website (http: / / cao.labshare.cn / AbRSA / cdrs.php), the abYsis website (www.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi) and the IMGT website (http: / / www.imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi#results). CDR herein includes overlaps and subsets of amino acid residues defined in different ways.
[0197] The term "Kabat numbering system" herein generally refers to the immunoglobulin alignment and numbering system proposed by Elvin A. Kabat (see, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991).
[0198] The term "Chothia numbering system" herein generally refers to the immunoglobulin numbering system proposed by Chothia et al., which is a classical rule for identifying the boundaries of CDR regions based on the positions of structural loop regions (see, e.g., Chothia, C., & Lesk, AM (1987). Canonical structures for the hypervariable regions of immunoglobulins. Journal of molecular biology, 196(4), 901-917.).
[0199] The term "IMGT numbering system" in this article generally refers to the numbering system based on the international ImMunoGeneTics information system (IMGT) initiated by Lefranc et al., see Lefranc, MP, Pommié, C., Ruiz, M., Giudicelli, V., Foulquier, E., Truong, L., ... & Lefranc, G. (2003). IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Developmental & Comparative Immunology, 27 (1), 55-77.
[0200] The term "heavy chain constant region" herein refers to the carboxyl terminal portion of the heavy chain of an antibody, which is not directly involved in the binding of the antibody to the antigen, but exhibits effector functions, such as interactions with Fc receptors, which have a more conservative amino acid sequence relative to the variable domains of the antibody. The "heavy chain constant region" can be selected from the CH1 domain, hinge region, CH2 domain, CH3 domain, or variants or fragments thereof. The "heavy chain constant region" includes a "full-length heavy chain constant region" and a "heavy chain constant region fragment", the former having a structure substantially similar to that of a natural antibody constant region, while the latter only includes "a portion of the full-length heavy chain constant region". Exemplarily, a typical "full-length antibody heavy chain constant region" consists of a CH1 domain-hinge region-CH2 domain-CH3 domain; when the antibody is an IgE, it also includes a CH4 domain; when the antibody is a heavy chain antibody, it does not include a CH1 domain. Exemplarily, a typical "heavy chain constant region fragment" can be selected from an Fc or CH3 domain.
[0201] The term "light chain constant region" herein refers to the carboxyl terminal portion of the antibody light chain, which is not directly involved in the binding of the antibody to an antigen, and the light chain constant region can be selected from a constant kappa domain or a constant lambda domain.
[0202] The term "Fc region" herein is used to define the C-terminal region containing at least a portion of the constant region in the antibody heavy chain. The term includes native sequence Fc regions and variant Fc regions. Exemplarily, the human IgG heavy chain Fc region can extend from Cys226 or Pro230 to the carboxyl terminus of the heavy chain. However, the antibody generated by the host cell can undergo post-translational cleavage, and one or more, particularly one or two amino acids are removed from the C-terminus of the heavy chain. Therefore, the antibody generated by the host cell through the expression of a specific nucleic acid molecule encoding a full-length heavy chain may include a full-length heavy chain, or it may include a cleavage variant of the full-length heavy chain. This may be the case when the final two C-terminal amino acids of the heavy chain are glycine (G446) and lysine (K447, numbering is according to the Kabat EU index). Therefore, the C-terminal lysine (Lys447) of the Fc region, or the C-terminal glycine (Gly446) and lysine (Lys447) may be present or absent. Typically, the IgG Fc region comprises an IgG CH2 and an IgG CH3 domain, and optionally, on this basis, may also comprise a complete or partial hinge region, but does not comprise a CH1 domain. The "CH2 domain" of the human IgG Fc region generally extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or a variant CH2 domain. The "CH3 domain" comprises the residues at the C-terminus of the CH2 domain in the Fc region (i.e., from an amino acid residue at about position 341 of IgG to an amino acid residue at about position 447). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having a "protuberance" or "knob" introduced in one of its chains and a "cavity" or "hole" introduced correspondingly in the other chain thereof; see U.S. Patent No. 5,821,333, expressly incorporated herein by reference). As described herein, such variant CH3 domains may be used to promote heterodimerization of two different antibody heavy chains.
[0203] Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0204] The term "mutation" or "variant" herein refers to a form of a polypeptide or protein in which the amino acid sequence differs from the amino acid sequence of its corresponding wild-type (parent) form, naturally occurring form, or any other parent form. A mutant polypeptide may comprise one or more mutations, e.g., substitutions, insertions, deletions, etc., which result in a mutant polypeptide. "Mutation" or "variant" are used interchangeably herein.
[0205] The term "antigen" herein is any substance that can induce an immune response and cause the immune system to produce antibodies, that is, it refers to a substance that can be recognized by the immune system and can, for example, trigger an antigen-specific immune response by forming antibodies as part of an adaptive immune response, such as antigen-specific T-cells, which are involved in the activation and / or antibody production of certain immune cells. Antigens are not only involved in antibody production. T cell receptors also recognize antigens. Any macromolecule, including almost all proteins or peptides, can be an antigen. Antigens can also be derived from genomic recombinants or DNA, for example, any DNA containing a nucleotide sequence or a partial nucleotide sequence encoding a protein that can induce an immune response encodes an "antigen". In some specific embodiments, the antigen does not need to be encoded only by the full-length nucleotide sequence of the gene, and the antigen does not need to be completely encoded by the gene. In some specific embodiments, the antigen can be synthesized or can be derived from a biological sample, such as a tissue sample, a tumor sample, a cell, or a fluid with other biological components. As used herein, "tumor antigens" or "cancer antigens" used interchangeably include any molecules that can stimulate an immune response that are present in cancer, for example, cancer cells or tumor microenvironments or are associated with them.
[0206] The term "cytokine" herein refers to the full length, fragment or variant of a naturally occurring wild-type cytokine (including fragments and functional variants having at least 10% activity of a naturally occurring cytokine). In some specific embodiments, the cytokine has at least 30%, 50% or 80% activity of a naturally occurring cytokine, such as immunomodulatory activity. In some specific embodiments, the cytokine also optionally comprises a receptor domain coupled to an immunoglobulin Fc region, such as a cytokine receptor domain. In other specific embodiments, the cytokine is coupled to an immunoglobulin Fc region. In other specific embodiments, the cytokine is coupled to an antibody (e.g., an immunoglobulin Fab or scFv fragment, a Fab fragment, a FAB2 fragment or an affinity body fragment or derivative, such as an sdAb (single domain antibody) fragment, a heavy chain antibody fragment, a single domain antibody, a bispecific or multispecific antibody).
[0207] The term "fusion protein" herein refers to a protein composed of at least two domains. The fusion protein herein can be a fusion protein formed by an anti-CD16 antibody and a cytokine IL15, or a fusion protein further formed by a fusion protein of an anti-CD16 antibody and a cytokine IL15 and a chimeric antigen receptor (CAR), wherein the fusion protein of the anti-CD16 antibody and the cytokine IL15 can be secreted outside the cell, and the chimeric antigen receptor (CAR) is expressed on the cell membrane.
[0208] The term "CD16" herein refers to the receptor type III (FcγRⅢ) for the Fc portion of immunoglobulin G, which is a group of differentiation molecules found on the surface of natural killer cells, neutrophils, monocytes, and macrophages. CD16 has been identified as the Fc receptor FcγRⅢa (CD16a) and FcγRⅢb (CD16b), which are involved in signal transduction. Human FcγRIIIA (CD16a) is a low-affinity receptor that can bind to IgG Fc and is expressed on human CD56-low expressing natural killer (NK) cells, monocyte subsets, dendritic cells, and rare T cells. Human FcγRIIIB (CD16b) is encoded by a different gene, is mainly expressed on neutrophils, is a GPI-anchored glycoprotein, and lacks the intracellular signal transduction domain. CD16a is a type I membrane glycoprotein with a single transmembrane (TM) domain and a short cytoplasmic tail. Its expression on the cell surface depends on binding to the signal transduction molecules CD247 (TCRζ) and / or Fc-εRI-γ. Once they interact, they induce a series of signal transductions, leading to cytokine release and cell killing activity.
[0209] The term "IL15" herein refers to interleukin 15, which is used interchangeably with "IL-15" and "interleukin-15". IL15 is a cytokine of the chemokine family that plays a role in NK cell development balance, proliferation, survival and activation. IL15 and IL-2 share several signal transduction components, including IL-2 / IL-15Rβ (CD122) and a common γ chain (CD132). IL15 also activates NK cells and restores functional defects in engrafted NK cells after hematopoietic stem cell transplantation (HSCT). Human IL15 is a cytokine produced by 1 The precursor protein consists of 62 amino acids, including a leader sequence consisting of 48 amino acids and a mature IL15 subunit consisting of 114 amino acids, and the molecule contains two disulfide bonds and two N-linked glycosylation sites. The IL15 described herein includes wild-type IL15 or variants thereof, and exemplary IL15 includes, for example, sequences shown in P40933·IL15_HUMAN (UniProt), NP_000576.1, NM_000585.4, NP_751915.1, and NM_172175.2.
[0210] The term "immune cell" herein refers to any of a variety of cells that play a role in the immune system, such as protecting against infection and foreign bodies, including white blood cells, such as neutrophils, eosinophils, basophils, lymphocytes and monocytes, and also includes immune effector cells described herein. "Immune cell" also refers to a modified form of a cell that participates in an immune response.
[0211] The term "immune effector cell" as used herein refers to a cell that participates in an immune response, such as promoting an immune effector response. Examples of immune effector cells include, but are not limited to, T cells, such as CD4 T cells, CD8 T cells, αT cells, 13T cells, γT cells, and δT cells; B cells; Natural killer (NK) cells; Natural killer T (NKT) cells; Dendritic cells; and mast cells. In some specific embodiments, the immune cell is an immune cell (e.g., a T cell or a NK cell) comprising, for example, expressing a chimeric antigen receptor (CAR), such as a CAR that binds a cancer antigen; in some specific embodiments, the immune cell expresses an exogenous high-affinity Fc receptor; in some specific embodiments, the immune cell comprises, for example, an engineered T cell receptor; in some specific embodiments, the immune cell is a tumor infiltrating lymphocyte; in some specific embodiments, the immune cell comprises an immune cell population, and comprises T cells that have been enriched specifically for tumor-associated antigens (TAAs); in some specific embodiments, the immune cell comprises an immune cell population, and comprises an antigen presenting cell (APC) that has been displayed with a TAA peptide of interest, such as a dendritic cell "trained" to have specificity for TAA; in some specific embodiments, in some specific embodiments, the immune cell comprises a T cell population that has been displayed with a plurality of TAA peptides of interest, such as a dendritic cell "trained" to have specificity for a plurality of TAAs. In some specific embodiments, the immune cell is a cytotoxic T cell (e.g., a CD8 T cell). In some specific embodiments, the immune cell is a helper T cell, such as a CD4 T cell.
[0212] As used herein, the term "effector function" or "effector response" refers to a specialized function of a cell.
[0213] As used herein, the term "autologous" refers to any material derived from the same individual that is subsequently reintroduced into that individual; the term "allogeneic" refers to any material derived from an animal of a different species than the individual into which the material was introduced.
[0214] The term "natural killer (NK) cell" herein is a cytotoxic lymphocyte of the innate immune system with immune surveillance capabilities. Like cytotoxic T cells, NK cells deliver many transmembrane and apoptosis-inducing granzymes and perforin particles. Unlike T cells, NK cells do not require antigen priming and recognize targets by engaging activation receptors in the absence of MHC recognition.
[0215] NK cells express CD16, an activating receptor that binds the Fc portion of IgG antibodies and participates in antibody-dependent cell-mediated cytotoxicity (ADCC). NK cells are regulated by IL15, which can induce increased antigen-dependent cytotoxicity, lymphokine-activated killing activity, and / or mediate interferon (IFN), tumor necrosis factor (TNF), and / or granulocyte macrophage colony-stimulating factor (GM-CSF) responses. These IL15-activated functions all contribute to improved cancer defense.
[0216] NK cells respond to various cytokines, including, for example, IL15, which is involved in NK cell homeostasis, proliferation, survival, activation and / or development. IL15 and IL2 share several signal transduction components, including IL2 / IL15Rβ (CD122) and a common γ chain (CD132). Unlike IL2, IL15 does not stimulate Treg, making it possible to activate NK cells when Treg inhibition of the immune response is bypassed. In addition to promoting NK cell balance and proliferation, IL15 can rescue NK cell functional defects that may occur in the post-transplant environment. IL15 also stimulates CD8+T cell function, further enhancing its immunotherapy potential. In addition, based on preclinical studies, the toxicity of IL15 may be more favorable than IL2 at low doses.
[0217] The term "PBNK" herein refers to peripheral blood natural killer cells, and different forms of CD16A on their cell surface will affect the affinity of CD16A to the Fc end of the antibody, for example, 158FF-PBNK or 158FV-PBNK or 158VV-PBNK. Specifically, for 158FF-PBNK, the amino acid at position 158 of its CD16A protein is phenylalanine (158F), and the affinity to Fc is low; for 158FV / VV-PBNK, when the amino acid at position 158 of its CD16A protein is valine (158V), the affinity to Fc is high.
[0218] As used herein, the term "immune cell antigen" includes any molecule present on or associated with an immune cell that can elicit an immune response.
[0219] The term "chimeric antigen receptor (CAR)" herein refers to an artificial cell surface receptor modified to express on immune effector cells and specifically bind to an antigen, which at least includes (1) an extracellular antigen binding domain, such as a heavy chain variable region and / or a light chain variable region of an antibody, (2) a transmembrane domain that anchors CAR into immune effector cells, and (3) an intracellular signaling domain. CAR can redirect T cells and other immune effector cells to selected targets, such as cancer cells, using the extracellular antigen binding domain in a non-MHC restricted manner. T cells transformed by CAR are referred to as "CAR-T cells", and accordingly, NK cells transformed by CAR are referred to as "CAR-NK cells".
[0220] The term "vector" herein refers to a self-replicating DNA molecule that transfers a DNA fragment (target gene) to a recipient cell in genetic engineering recombinant DNA technology. The term includes vectors that are self-replicating nucleic acid structures and vectors that are integrated into the genome of the host cell into which the vector has been introduced. Certain vectors are capable of directing the expression of nucleic acids that are operably linked to them. The three most commonly used vectors are bacterial plasmids, bacteriophages, and animal and plant viruses. Specifically, suitable vectors include retroviruses, adenoviruses, adenovirus-associated viruses, poxviruses, and bacterial plasmids.
[0221] The term "pharmaceutical composition" herein refers to a preparation which is in a form which permits the biological activity of the active ingredient contained therein to be effective, and which contains no additional ingredients which are unacceptably toxic to a subject to which the pharmaceutical composition is administered.
[0222] The term "pharmaceutically acceptable carrier" herein includes any and all solvents, dispersion media, coating materials, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc. and combinations thereof, which are known to those skilled in the art. Except for situations where they are incompatible with the active ingredient, any conventional carrier is considered for use in treatment or pharmaceutical compositions.
[0223] The term "treatment" herein refers to surgical or therapeutic treatment, the purpose of which is to prevent, slow down (reduce) undesirable physiological changes or lesions in the treated subject, such as cancer and tumors. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction of disease severity, stabilization of the disease state (i.e., no deterioration), delay or slowing of disease progression, improvement or alleviation of the disease state, and relief (whether partial relief or complete relief), whether detectable or undetectable. Subjects in need of treatment include subjects who already have a disorder or disease, as well as subjects who are susceptible to a disorder or disease or subjects who intend to prevent a disorder or disease. When referring to terms such as slowing down, alleviating, weakening, alleviating, and alleviating, their meanings also include situations such as elimination, disappearance, and non-occurrence.
[0224] The term "subject" herein refers to an organism that is treated for a particular disease or condition as described herein. Exemplarily, a "subject" includes a mammal, such as a human, a primate (e.g., a monkey), or a non-primate mammal that is treated for a disease or condition.
[0225] The term "effective amount" refers to an amount of a therapeutic agent that is effective in preventing or alleviating a disease condition or the progression of the disease when administered alone or in combination with another therapeutic agent to a cell, tissue, or subject. "Effective amount" also refers to an amount of a compound sufficient to relieve symptoms, such as to treat, cure, prevent, or alleviate a related medical condition, or to increase the rate of treatment, cure, prevent, or alleviate these conditions. When an active ingredient is administered to an individual alone, a therapeutically effective dose refers to that ingredient alone. When a combination is used, a therapeutically effective dose refers to the combined amounts of the active ingredients that produce a therapeutic effect, whether administered in combination, sequentially, or simultaneously.
[0226] The term "tumour" herein refers to a new growth formed by the proliferation of local tissue cells under the action of various tumorigenic factors. Because this new growth is mostly a space-occupying block-like protrusion, it is also called a neoplasm. The tumor described herein can cover all types of tumorigenic processes and / or cancerous growths. In some specific embodiments, the tumor includes primary tumors and metastatic tissues or malignantly transformed cells, tissues or organs. In some specific embodiments, the tumor covers all histopathologies and stages of the tumor, such as the invasive / severity stage. In some specific embodiments, the tumor includes recurrent and / or drug-resistant tumors. The terms "tumor" and "cancer" herein can be used interchangeably. Exemplarily, both terms include solid tumors and liquid tumors. As used herein, the term "tumor" or "cancer" includes pre-malignant and malignant cancers and tumors. DETAILED DESCRIPTION
[0227] The present invention will be further described below in conjunction with specific examples, and the advantages and features of the present invention will become clearer as the description proceeds. Where specific conditions are not specified in the examples, conventional conditions or conditions recommended by the manufacturer are used. Where the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0228] The embodiments of the present invention are only exemplary and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.
[0229] General Methods
[0230] Biacore (SPR method) to detect antibody affinity
[0231] Recombinant candidate antibodies were captured using Protein A chips (GE Healthcare; 29-127-558). Sample and running buffer were HBS-EP+ (10mM HEPES, 150mM NaCl, 3mM EDTA, 0.05% surfactant P20) (GE Healthcare; BR-1006-69). The flow-through pool was set to 25°C. The sample block was set to 16°C. Both were pretreated with running buffer. In each cycle, the antibody to be tested was first captured with a Protein A chip, then a single concentration of antigen protein was injected, the binding and dissociation process of the antibody and antigen protein was recorded, and finally the chip was regenerated with Glycine pH1.5 (GE Healthcare; BR-1003-54). Binding was measured by injecting different concentrations of human antigen protein in solution for 240 seconds, with a flow rate of 30 μL / min, starting from 200nM (see detailed results for the actual concentration tested), diluted 1:1, and a total of 5 concentrations. The dissociation phase was monitored for up to 600 seconds and triggered by switching from the sample solution to the running buffer. The surface was regenerated by washing with a 10 mM glycine solution (pH 1.5) at a flow rate of 30 μL / min for 30 seconds. Bulk refractive index differences were corrected by subtracting the response obtained from the goat anti-human Fc surface. Blank injections (= double reference) were also subtracted. For the calculation of apparent KD and other kinetic parameters, the Langmuir 1:1 model was used. The association rate (Ka), dissociation rate (Kdis) and binding affinity (KD) were calculated.
[0232] Unless otherwise specified, the target cells referred to in the following examples are all transferred with luciferase genes to express luciferase. The fluorescence intensity is detected by a luciferase reporter gene detection reagent to reflect the cell viability and the killing effect of NK cells. The killing rate calculation formula is as follows:
[0233] Killing rate = (target cell well reading - test well reading) / target cell well reading × 100%
[0234] Example 1. Preparation of antibodies
[0235] 1.1 Preparation of anti-BCMA nanobodies
[0236] Anti-BCMA nanoantibodies were prepared by immunizing alpacas, first with human BCMA (Met1-Ala54)-hFc protein, and then with a mixed booster immunization of human BCMA (Met1-Ala54)-hFc protein and cynomolgus monkey BCMA (Met1-Ala53)-hFc protein. Blood was collected one week after each booster immunization, and the serum antibody titer and specificity were tested by ELISA. After verifying that the serum had different degrees of binding to both human BCMA-hFc and cynomolgus monkey BCMA-hFc proteins, subsequent phage library construction and panning were performed.
[0237] Peripheral blood was collected, PBMC was separated, total RNA was extracted, reverse transcription was performed to prepare cDNA, and nested amplification was performed to obtain VHH fragments. After both the VHH fragments and the vectors were digested and ligated, the ligated products were transformed by electroporation and cultured on plates. After overnight, the E. coli library was expanded and cultured. Helper phage M13K07 was added, cultured and its titer was determined. ELISA was used to identify and select clones with high positive rates for binding to human and monkey BCMA proteins in multiple rounds. The positive clones were sent for sequencing and cluster analysis.
[0238] Using ELISA and Biacore methods well known to those skilled in the art, VHH antibodies with good binding to human and monkey BCMA proteins were screened and identified for humanized design. By comparing the IMGT (http: / / imgt.cines.fr) human antibody heavy and light chain variable region germline gene database, the heavy chain variable region germline genes with high homology to the VHH nanobody were selected as templates, and the CDRs were transplanted into the corresponding human templates. As needed, the key amino acids in the framework sequence were reversed to the amino acids corresponding to the VHH nanobody to ensure the original affinity. At the same time, if there are sites that are prone to chemical modification in the antibody, these sites have been point mutated to eliminate the risk of modification, and humanized monoclonal antibodies were obtained. The CDR amino acid residues of the antibody were determined and annotated by the Kabat numbering system. It was then verified by Biacore. Finally, the following alpaca-derived VHH antibody was obtained, named BCMA-Lab02; its humanized anti-BCMA antibody was named BCMA-Hab02-VHH7. The Biacore affinity determination data are shown in Table 1. The antibody sequences are shown in Table 2, and the Kabat numbered CDR sequences are shown in Table 3.
[0239] Table 1 Affinity of BCMA-Lab02 and its humanized antibodies to human BCMA protein
[0240] Antibody Name <![CDATA[K a (1 / Ms)]]> <![CDATA[K dis (1 / s)]]> KD(M) BCMA-Lab02 7.38E+05 4.47E-05 6.06E-11 BCMA-Hab02-VHH7 8.05E+05 7.10E-05 8.82E-11
[0241] Table 2 Anti-BCMA Nanobody Sequence List
[0242]
[0243] Table 3 Anti-BCMA Nanobody Kabat Numbering CDR Sequence List
[0244]
[0245] 1.2 Preparation of anti-GPRC5D nanobody
[0246] Preparation of camel-derived VHH antibodies: Select camels of about 3 weeks old, collect 5 ml of blood before immunization, and keep it as negative control serum. Human GPRC5D protein was used for the first three immunizations, followed by four immunizations with CHO-K1-human GPRC5D overexpression cell lines. After verifying that the serum binds to both human and monkey GPRC5D proteins, the phage library was constructed and screened. PBMC was isolated from peripheral blood, total RNA was extracted, and cDNA was obtained by reverse transcription. Nested PCR was used to amplify the nanobody (VHH) fragment. The vector and the target product were digested and ligated, and then the ligation product was electroporated into TG1 competent cells and diluted for plate culture. After overnight expansion, the helper phage M13K07 was added, cultured, and its titer was determined.
[0247] Phage library panning was performed using human GPRC5D overexpressing cells as antigens. After multiple rounds of panning, positive phages were continuously enriched during the panning process, and nano antibodies with good specificity and high affinity for overexpressing cells and endogenously expressing human GPRC5D were screened using FACS. After multiple rounds of optimization and screening, a total of several positive clones that can simultaneously recognize human and monkey GPRC5D were obtained. Sequencing, reference to Example 1.1, the construction of humanized antibodies, the CDRs of which are annotated by IMGT or Kabat. After FACS verification, several strains of humanized antibodies with higher affinity were obtained. Finally, a camel antibody was obtained and named GPRC5D-Lab05, and its humanized antibody was named GPRC5D-Hab05-H2. The binding activity of the antibody to human GPRC5D overexpressing cells and multiple myeloma cells is shown in Table 4. The nano antibody sequence is shown in Table 5, and the IMGT numbered CDRs sequence is shown in Table 6.
[0248] Table 4 Binding activity of GPRC5D-Lab05 and its humanized antibodies to cells
[0249]
[0250] Table 5 Anti-GPRC5D Nanobody Amino Acid Sequences
[0251]
[0252] Table 6 Anti-GPRC5D Nanobody IMGT Numbering CDR Sequences
[0253]
[0254] 1.3 Preparation of anti-CD16 nanobody
[0255] Anti-CD16 nanobodies were prepared by immunizing alpacas, and human CD16a (158F)-hFc and human CD16a (158V)-hFc proteins were used for immunization. One alpaca (Llama) was selected for immunization. Each alpaca was immunized four times, with an interval of 3 weeks each time. Peripheral blood was collected after the third and fourth immunizations, and serum was separated. The antibody titer and specificity against human CD16 in the serum were detected by enzyme-linked immunosorbent assay (ELISA). After verifying that the serum had different degrees of binding to both human CD16 and cynomolgus monkey CD16 proteins, subsequent phage library construction and panning were carried out. After multiple rounds of panning, positive phages were continuously enriched during the panning process, and FACS was used to screen out nanobodies with good specificity and high affinity for overexpressing cells and cells endogenously expressing human CD16. After multiple rounds of optimization and screening, a total of several positive clones that can simultaneously recognize human and monkey CD16 were obtained.
[0256] Using the ELISA and Biacore methods well known to those skilled in the art, VHH antibodies that bind well to human and monkey CD16 proteins were screened and identified for humanized design. By comparing the IMGT (http: / / imgt.cines.fr) human antibody heavy and light chain variable region germline gene database, the heavy chain variable region germline genes with high homology to the VHH nanobody were selected as templates, and the CDRs were transplanted into the corresponding human templates. As needed, the key amino acids in the framework sequence were reversed to the amino acids corresponding to the VHH nanobody to ensure the original affinity. At the same time, if there are sites that are prone to chemical modification in the antibody, these sites have been point mutated to eliminate the risk of modification, and humanized monoclonal antibodies were obtained. The CDR amino acid residues of the antibody are determined and annotated by the Kabat numbering system. Subsequently, after Biacore verification, the alpaca-derived VHH antibody was finally obtained, and its humanized anti-CD16 antibody was named CD16VHH. The CD16VHH sequence and CDR sequence used in this article are shown in Tables 7 and 8:
[0257] Table 7 Anti-CD16 Nanobody Amino Acid Sequences
[0258]
[0259] Table 8 Anti-CD16 Nanobody IMGT Numbering CDR Sequences
[0260]
[0261] The affinity determination results of the obtained CD16 antibodies with human CD16a-ECD-his protein, human CD16b-ECD-his protein, and monkey CD16-ECD-his protein, including the association rate (ka), dissociation rate (kd) and binding affinity (KD), are shown in Tables 9-12, respectively.
[0262] Table 9 Biacore detection of the binding of CD16 antibody to human CD16a protein
[0263]
[0264] Table 10 Biacore detection of the binding of CD16 antibody to human CD16b protein
[0265]
[0266] Table 11Biacore detection of the binding of CD16 antibody to human CD16b protein
[0267]
[0268] Table 12 Biacore detection of the binding of CD16 antibody to monkey CD16 protein
[0269]
[0270] Example 2. Preparation of chimeric antigen receptors and fusion proteins
[0271] 2.1 Design of chimeric antigen receptors
[0272] In order to verify the effect of the fusion protein on the activity of the chimeric antigen receptor, the BCMA-VHH antibody and GPRC5D-VHH antibody screened in Example 1 were used to design and construct the following Figure 1 The fusion protein BC-1 formed by the dual-target chimeric antigen receptor targeting BCMA and GPRC5D is shown (see Figure 1 ).
[0273] The dual-target chimeric antigen receptor targeting BCMA and GPRC5D includes CD8α signal peptide (SP), anti-BCMA-VHH and anti-GPRC5D-VHH, CD8 hinge region, NKG2D transmembrane region (NKG2D-TM), 2B4 co-stimulatory domain and CD3ζ. The dual-target chimeric antigen receptor is connected to CD16VHH-IL15 through the self-cleaving peptide P2A (or T2A) to form a fusion protein BC-1.
[0274] The main design and component composition of the control-IL15 molecule and BC-1 described in this paper are summarized as follows (see Figure 1 , italic bold is CD16VHH-IL15 structure):
[0275] BC-1: CD8α―anti-BCMA-VHH―connector peptide-1―anti-GPRC5D-VHH―CD8α hinge region―NKG2D-TM―2B4 intracellular domain―CD3ζ―P2A―CD8α-SP―CD16VHH―connector peptide-2―sIL15-1;
[0276] control-IL15 molecule: CD8α―anti-BCMA-VHH―connector peptide-1―anti-GPRC5D-VHH―CD8α hinge region―NKG2D-TM―2B4 intracellular domain―CD3ζ―P2A―sIL15-
[0277] The amino acid sequences of each domain in control-IL15 and BC-1 described in this article are detailed in Table 13.
[0278] Table 13 Amino acid sequence table of chimeric antigen receptor, fusion protein domains and exemplary fusion proteins
[0279]
[0280]
[0281]
[0282]
[0283] 2.2 Construction of target plasmid
[0284] The conventional molecular biological methods in the art were used to load the nucleic acid sequence of the chimeric antigen receptor into the retroviral vector to construct the target plasmid. The specific steps are as follows: the CAR nucleotide sequence was amplified and obtained by PCR, and the target gene fragment was subjected to double restriction digestion reaction with the retroviral vector plasmid, and incubated at 37 ° C for 60 min. After the restriction reaction, the nucleic acid fragment was purified by agarose gel (using Taraka gel purification kit), and the specific operation steps were carried out according to the kit operation manual. The target nucleic acid molecule after gel purification was incubated at 16 ° C for 10-12 h under the action of T4 ligase, and the obtained ligation product was transferred into DH5α competent cells by heat shock, and the obtained competent cells were transferred into liquid LB medium without antibiotics, shaken at 37 ° C for 200 rpm, cultured for 2 h, and then centrifuged at 4000 rpm for 2 min, and then centrifuged and resuspended in fresh LB medium, and the bacterial solution was evenly applied to the solid LB medium containing antibiotics, cultured overnight in a 37 ° C incubator, and the positive clones were picked and identified, and the target plasmid of the positive clones was extracted for standby.
[0285] 2.3 Virus packaging
[0286] One day before virus packaging, 293T cells (purchased from ATCC) were trypsinized and cultured at 1×10 7 When transfecting cells, mix the packaging plasmid and the target plasmid and add them to the α-MEM medium. In another centrifuge tube containing α-MEM medium, add HD transfection reagent (Promega, E2311). Add the diluted transfection reagent dropwise to the diluted plasmid, mix well, and let stand at room temperature for 15 minutes. Finally, add the mixture of plasmid and transfection reagent to a 10cm culture dish, shake gently 10 times, mix well, and put it in the incubator. 3 days after cell transfection, harvest the virus, transfer 10ml of virus-containing culture supernatant into a 50ml centrifuge tube, 4℃, 1250rpm, 5 minutes, remove dead 293T cells, filter the virus-containing supernatant, and concentrate it using a centrifugal filter (Merck, UFC903096), and store it at -80℃ for later use after aliquoting.
[0287] 2.4 Methods of inducing PBMC into NK cells and activation of NK cells
[0288] Fresh PBMCs were centrifuged at 500g for 7 minutes at room temperature, and the upper culture medium was discarded and NK cells were isolated according to the Human NK Cell Isolation Kit (Stemcell, 17955). The isolated NK cells were activated with K562 cells, and the activation method was as follows: Day 0, counted with AO / PI, mixed cells according to NK:K562=1:2, and added to the Non-Treated 6-well plate at 2ml / well (the culture medium was NK cell culture medium containing 200IU / ml human IL2 (Miltenyi Biotec, 130-114-429)), and placed in an incubator for culture (37°C, 5% CO2); Day 4, 3mL of culture medium was added to each well; Day 6, cell activation was completed and transfection was possible.
[0289] 2.5 Detection of virus-infected NK cell titer
[0290] On Day 1, 24-well plates were coated with 7μg / mL RetroNectin reagent (Takara, T202), 500μL per well, overnight at 4°C. On Day 2, the upper layer of RetroNectin was discarded and washed once with PBS. 3E5 NK cells were infected with 400ul, 200ul, 100ul, 50ul, 25ul, and 12.5ul of virus respectively. The 24-well plates with added viruses were centrifuged at 1000g, 4-8°C for 60min. The 24-well plates were cultured in an incubator (37°C, 5% CO2). On Day 3, the transfected NKs were transferred to Non-Treated 6-well plates. On the 6th day after retrovirus infection of NK cells, the expression rate of CAR on the surface of NK cell membrane was detected by flow cytometry. The method for detecting the expression of BCMA-CAR NK surface molecules in control-IL15 and BC molecules is as follows: take 2×10 5 The cells were transferred to a 96-well U-shaped plate and centrifuged. The supernatant was discarded. After washing with buffer, 100 μl of FITC-hBCMA-Fc (ACRO Biosystems, BCA-HF254) with a final concentration of 2 μg / ml was added and incubated at 4°C in the dark for 1 hour. After the incubation, the cells were centrifuged, the supernatant was discarded, and the cells were resuspended after washing with buffer. The expression rate of BCMA-CAR was detected by BD FACS Canto II flow cytometer.
[0291] CAR+% and MFI statistics at different virus dosages are shown in Figure 2A-2B , the longer the target gene inserted in the vector at the same virus dosage, the lower the CAR+% and the lower the MFI value. At the same virus dosage, the CAR+% and MFI values of the control-IL15 molecule were higher than those of BC-1.
[0292] 2.6 Multiple rounds of killing effect detection of fusion protein
[0293] After the target molecules were prepared, the killing ability of control-IL15 and BC-1 molecules was preliminarily verified. The in vitro multiple rounds of killing effects of control-IL15 and BC-1 on NCI H929 cells were detected on the 7th day after retrovirus infection of PBNK cells: (1) First round of killing: 2.5×10 5 Target cells NCI H929 diluted with 1640 medium were placed in a 12-well plate at a ratio of 1:2. NK cells were added to the 12-well plate at a ratio of 1:2 and cultured in a 37°C, 5% CO2 incubator for 24 hours. After 48 hours of culture, 100 μl of the above mixed cells were added to a 96-well plate with a white bottom and opaque, and 30 μl of FIREFLYGLO luciferase reporter gene detection reagent (Mei Lun Bio, MA0519-1) was added. After incubation at room temperature and away from light for 10 minutes, the fluorescence intensity was measured with an ELISA instrument to calculate the NK cell killing efficiency. After that, the next round of killing test was carried out. (2) Next round of killing: Take the cells in the 12-well plate in the previous round, count the NK cells, add the NK cells in the previous round to the 12-well plate inoculated with new target cells at a ratio of 1:2, repeat step (1), measure the NK cell killing rate and continue the next round of killing test.
[0294] The results of multiple rounds of killing experiments with cells loaded with control-IL15 and BC-1 are shown in Figure 3 .like Figure 3 As shown, BC-1 cells loaded with CD16VHH-IL15 have a better killing effect on NCI H929 tumor cells than control-IL15 cells; among them, BC-1 can maintain a cell killing rate of more than 80% in the third round of killing (R3) of NCI H929 cells, and control-IL15 cells can maintain a cell killing rate of more than 70% in the third round of killing (R3) of NCI H929 cells.
[0295] Example 3. Second in vitro evaluation of the killing effect of fusion protein
[0296] 3.1 Fusion protein titer detection
[0297] The virus was packaged using the method described in Example 2.3, and the virus was concentrated using a centrifugal filter (Merck, UFC903096). After packaging, the virus was stored at -80°C for later use. The titer of the prepared virus was tested on activated NK cells using the method described in Example 2.5. The titer test results are shown in Figure 4At the same virus dosage, the longer the target gene inserted into the vector, the lower the CAR+%, among which the virus titer of control-IL15 molecule was 1.59e7 pfu / ml, and the virus titer of BC-1 was 0.39e7 pfu / ml.
[0298] 3.2 Detection of fusion protein expression
[0299] Referring to the method shown in Example 2.5, PBNK cells were infected with MOI=4 to prepare control-IL15 cells and BC-1 cells, and the expression of CAR was detected. Figure 5 The statistical results of anti-BCMA CAR expression data are shown in Table 14. The results showed that under the condition of MOI=4, the CAR+% of control-IL15 cells and BC-1 cells could reach more than 90%, and there was no significant difference between different structures.
[0300] Table 14 BC-1 expression rate detection
[0301] BI-CAR BCMA-CAR expression control-IL15 92.5% BC-1 93.5% PNBK 2.96%
[0302] 3.3 Determination of fusion protein proliferation rate
[0303] The proliferation of BC NK cells was detected by AO / PI counting. Figure 6 As shown. After 17 days of NK activation, the proliferation rates of BC NK cells were as follows: control-IL15 (4503 times) > BC-1 (3950 times) > PBNK (1975 times). According to the above results, there is no significant difference in the cell proliferation rate between different structures of fusion protein, but it is significantly better than PBNK cells.
[0304] 3.4 Detection of cell surface markers in cells expressing fusion proteins
[0305] Flow cytometry was used to detect the expression of markers on the surface of NK cells after 17 days of activation. The detected markers included CD56 (BD, 560916), CD16 (BD, 556618), CD38 (BD, 562445), IL15 (ThermoFisher, MA5-23561), CD69 (BD, 562884), etc.
[0306] CD56 expression rate Fig. 7A As shown, the expression rate of CD56 in each experimental group was above 99%.
[0307] The expression rate of CD16 Figure 7BAs shown, the highest CD16 expression rate was in BC-1 cells (83.4%), followed by control-IL15 cells (78.4%), and the lowest was in the PBNK group (51.0%).
[0308] CD38 expression Figure 7C As shown, the expression rates of CD38 in control-IL15 and BC-1 were significantly lower than those in PBNK, followed by BC-1 (14.0%) <control-IL15(28.0%)<PBNK(56.1%)。
[0309] Expression of activation marker CD69 Fig.7D As shown, the expression rates of CD69 were PBNK (41.1%) > BC-1 (31.3%) > control-IL15 (23.5%).
[0310] 3.5 Multiple rounds of killing effect detection of fusion protein
[0311] On the 11th day after retroviral infection of NK cells, the in vitro multiple rounds of killing effects of control-IL15 and BC-1 on NCI H929 cells were detected: (1) First round of killing: 2.5×10 5 Target cells NCI H929 diluted with 1640 medium were placed in a 12-well plate at a ratio of 1:3. NK cells were added to the 12-well plate at a ratio of 1:3 and cultured in a 37°C, 5% CO2 incubator for 72 hours. After 72 hours of culture, 100 μl of the above mixed cells were added to a 96-well plate with a white bottom and opaque, and 30 μl of FIREFLYGLO luciferase reporter gene detection reagent (Mei Lun Bio, MA0519-1) was added. After incubation at room temperature and away from light for 10 minutes, the fluorescence intensity was measured with an ELISA instrument to calculate the NK cell killing efficiency. After that, the next round of killing test was carried out. (2) Next round of killing: Take the cells in the 12-well plate in the previous round, count the NK cells, add the NK cells in the previous round to the 12-well plate inoculated with new target cells at a ratio of 1:3, repeat step (1), measure the NK cell killing rate and continue the next round of killing test.
[0312] The results of multiple rounds of killing experiments on NCI H929 cells by cells loaded with control-IL15 and BC-1 are shown in Figure 8 .like Figure 8 As shown, the killing effect of BC-1 loaded with CD16VHH-IL15 element is better than that of control-IL15 molecule; BC-1 can still maintain a 50% cell killing rate in the third round of killing of NCI H929 cells.
[0313] 3.6 Rapid killing rate determination of fusion protein after 2 weeks of cryopreservation at 4 h
[0314] 4h in vitro rapid killing experiment of control-IL15 and BC-1 at 0h after resuscitation: target cells NCI H929 or Molp8 diluted in 1640 medium were inoculated at 2×10 4 50 μl / well were added to a white opaque 96-well plate, and NK cells were added to the above target cells at effector-target ratios of 5:1, 2.5:1, 1.25:1, and 0.625:1, and the 96-well plate was cultured in a 37°C, 5% CO2 incubator; after 4 hours, 30 μl of FIREFLYGLO luciferase reporter gene detection reagent (Mei Lun Bio, MA0519-1) was added, and after incubation at room temperature in the dark for 10 minutes, the killing rate was measured using a microplate reader and calculated.
[0315] The 4-hour in vitro cell killing effect of control-IL15 cells and BC-1 cells on NCI H929 target cells is as follows Fig. 9A The killing efficiency statistics are shown in Table 15. The results showed that both control-IL15 and BC-1 showed strong killing function against tumor cells, and the killing function of BC-1 cells against NCI H929 cells was slightly better than that of control-IL15 cells at low E:T ratio.
[0316] Table 15 Results of 4h rapid killing rate of CAR-NK cells with different structures
[0317]
[0318] Note: “-” means no killing effect was detected.
[0319] The 4-h in vitro cell killing effect of control-IL15 cells and BC-1 cells on Molp8 target cells is as follows Fig. 9B The killing efficiency statistics are shown in Table 16. The results showed that BC-1 had better killing function on Molp8 tumor cells than control-IL15.
[0320] Table 16 Results of 4h rapid killing rate of CAR-NK cells with different structures
[0321]
[0322]
[0323] Note: “-” means no killing effect was detected.
[0324] 3.7 RTCA method to detect the killing effect of fusion protein on target cells after 2 weeks of cryopreservation
[0325] Long-term in vitro killing experiment of control-IL15 and BC-1 on CHOK1-hBCMA, CHOK1-hGPRC5D, and mixed cells of CHOK1-hBCMA and CHOK1-hGPRC5D at 0 hours after recovery: The experiment was carried out according to the cell killing experiment operation steps with a target-effect ratio of 1:1 in the xCELLigence RTCA instrument operation manual. The target cells selected were CHOK1-hBCMA, CHOK1-hGPRC5D, and mixed cells of CHOK1-hBCMA and CHOK1-hGPRC5D cells mixed at a ratio of 1:1, and diluted to 2×10 with DMEM / F-12 medium. 4 / 50μl / well, control-IL15 and BC-1 cells were diluted to 2×10 with DMEM / F-12 medium. 4 / 50μl / well. When the cell index is close to 0, the next round of killing experiment can be entered. The killing efficiency of control-IL15 and BC-1 cells on target cells is detected in real time by the instrument. The long-term in vitro killing effect is shown in Figure 10. As shown in Figure 10, BC-1 cells showed stronger killing function against CHOK1-hBCMA, CHOK1-hGPRC5D, and mixed cells of CHOK1-hBCMA and CHOK1-hGPRC5D at 0 hours after recovery.
[0326] 3.8 Detection of IFN-γ secretion after cryopreserved fusion protein kills target cells
[0327] After the control-IL15 and BC-1 kill the target cells in one round in Example 3.7, the supernatant is taken for IFN-γ detection. The experimental steps are carried out according to the instructions of the IFN-γ kit (BD, 555142). Fig.11 As shown, at 0 h after recovery, BC-1 cells produced significantly more IFN-γ than control-IL15 during cell killing by CHOK1-hBCMA, CHOK1-hGPRC5D, and a mixture of CHOK1-hBCMA and CHOK1-hGPRC5D.
[0328] Example 4 Preparation and functional evaluation of CAR-NK targeting CD19
[0329] 4.1 Preparation of CD19 CAR-NK cells
[0330] Reference Fig.12, construct a chimeric antigen receptor structure targeting CD19 for NK cells, clone the nucleic acid encoding the chimeric antigen receptor for NK cells into a retroviral shuttle plasmid, and perform viral packaging through a packaging plasmid. For specific experimental steps, refer to Example 2. The sequence of the CD19 single-chain antibody (scFv) used in the construction of a chimeric antigen receptor targeting CD19 and the corresponding CDR sequence are shown in Tables 17 and 18.
[0331] Table 17 Anti-CD19 single chain antibody amino acid sequence
[0332]
[0333] Table 18 Anti-CD19 single chain antibody Kabat numbering CDR sequences
[0334]
[0335]
[0336] 4.2 Detection of CD19 CAR amplification and transfection efficiency
[0337] The proliferation of NK cells during the culture process after virus transfection was detected (amplification multiple statistics from Day 6 to Day 15). The results are as follows Fig.13 As shown in the figure. After NK cells were transfected with CD19-CAR2 structure, the expansion multiple was equivalent to that of PBNK, and the expansion multiple on Day15 was about 360 times. After NK cells were transfected with CD19-CAR1 and CD19-CAR3 structures, the in vitro expansion ability was effectively improved compared with PBNK and CD19-CAR2, and the expansion multiple on Day15 was 750 times. This shows that sIL15 and CD16VHH-sIL15-1 fusion protein contribute to the in vitro expansion of CAR-NK.
[0338] On the 7th day after transfection, CAR expression was detected and analyzed using a flow cytometer (BD, CANTOII). CD19 CAR transfection efficiency (%) and MFI results are shown in Fig.14 and Fig.15 As shown, the expression rates and MFIs of PBNK, CD19-CAR1, CD19-CAR2 and 18.2-CAR3 were 0.13%, 78.1%, 71.1% and 77.3%; 68.3, 1569, 1271 and 1560, respectively. Each CAR structure showed good viral transfection efficiency.
[0339] 4.3 Detection of the killing effect of CD19 CAR-NK cells on tumor cells with high expression of CD19
[0340] 4h tumor cell killing experiment: 20,000 adult B-type acute lymphoblastic leukemia cell line target cells Nalm6-luc (carrying luciferase gene) were plated on a 96-well plate. Different structures of CAR-NK cells or PBNK were added for co-culture at E:T ratios of 1:2, 1:4, 1:8 and 1:16 respectively. Samples were taken after 4 hours, and the firefly luciferase substrate D-Luciferin (Abcam, Cat#ab143655) was added. The bioluminescence value (PE EnSight microplate reader) was read to calculate and analyze the killing rate. The results are shown in Figure 2. Fig.16 As shown. Compared with PBNK, the three CAR-transduced NK cells showed strong killing activity against Nalm6-luc cells in a short time. At a low E:T ratio, the killing efficiency of CD19-CAR3 against Nalm6-luc cells was significantly higher than that of NK cells transduced with other CAR structures. Correspondingly, the killing effect of NK cells transduced with CD19-CAR2 structure at a low E:T ratio was similar to that of PBNK cells.
[0341] Multiple rounds of continuous killing experiments: 40,000 Nalm6-luc cells / well were plated on a 96-well plate and co-cultured at a ratio of NK cells: target cells = 1:3. Samples were taken after 24 or 48 hours, and the bioluminescence value was read using a PE EnSight microplate reader to calculate the killing rate. The co-cultured cells were resuspended, and 1 / 2 volume of the cell suspension was taken and co-cultured with the same number of fresh Nalm6-luc cells for the next round of killing experiments. And so on, a total of 3 rounds of killing were completed. The results are shown in the figure. Fig.17 As shown, CD19-CAR2 cells only showed killing ability in the first round of killing experiments, and the killing ability and persistence were significantly reduced in the second round of killing experiments. Correspondingly, CD19-CAR1 cells carrying sIL15 showed 100% killing efficiency since the second round of killing experiments, but did not show effective killing ability in the third round of killing experiments. NK cells transduced with the CD19-CAR3 structure carrying the CD16VHH-sIL15-1 fusion protein showed persistent killing ability against Nalm6-luc cells and significantly extended the killing persistence to the third round. The killing efficiency of the CD19-CAR3 structure at the end of the third round was 20%. The results of multiple rounds of continuous killing experiments were similar to those of short-term killing experiments. Among the three CAR structures, the killing efficiency of CD19-CAR3 was better than that of CD19-CAR1 and CD19-CAR2.
[0342] The teachings of all patents, published applications, and references cited herein are incorporated by reference in their entirety.
[0343] While example embodiments have been particularly shown and described, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the embodiments as covered by the appended claims.
Claims
1. A cell, characterized in that The cell comprises a fusion protein or a nucleic acid encoding the fusion protein, wherein the fusion protein comprises an anti-CD16 antibody and a cytokine IL15; preferably, the fusion protein is secreted by the cell.
2. The cell according to claim 1, characterized in that The anti-CD16 antibody and the cytokine IL15 in the fusion protein are sequentially connected via a connecting peptide 2; Optionally, the anti-CD16 antibody is Fab, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody or nanobody; Preferably, the connecting peptide 2 comprises the amino acid sequence shown in SEQ ID NO:
28.
3. The cell according to claim 1 or 2, characterized in that The anti-CD16 antibody comprises all three CDRs of the amino acid sequence shown in SEQ ID NO: 14, wherein the CDRs are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system; Preferably, determined using the IMGT numbering system, the three CDRs of the anti-CD16 antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 15, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 16, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:
17.
4. The cell according to any one of claims 1 to 3, characterized in that The anti-CD16 antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 14; Preferably, the anti-CD16 antibody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 14; More preferably, the anti-CD16 antibody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 14; Preferably, the anti-CD16 antibody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 14; More preferably, the anti-CD16 antibody comprises the amino acid sequence shown in SEQ ID NO:
14.
5. The cell according to any one of claims 1 to 4, characterized in that The cytokine IL15 is wild-type IL15 or a mutant thereof; Preferably, the cytokine IL15 comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26; More preferably, the cytokine IL15 comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26; More preferably, the cytokine IL15 comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26; Preferably, the cytokine IL15 comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:26; More preferably, the cytokine IL15 comprises the amino acid sequence shown in SEQ ID NO:25 or SEQ ID NO:
26.
6. The cell according to any one of claims 1 to 5, characterized in that The fusion protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; Preferably, the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; More preferably, the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; Preferably, the fusion protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; More preferably, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:
30.
7. The cell according to any one of claims 1 to 6, characterized in that The cell is an immune effector cell, preferably, the immune effector cell is selected from NK cells (natural killer cells), NKT cells (natural killer T cells), T cells, monocytes, macrophages, dendritic cells or mast cells; Preferably, the immune effector cells are NK cells; Preferably, the immune effector cells are autologous immune effector cells or allogeneic immune effector cells.
8. A fusion protein, characterized in that The fusion protein is a fusion protein comprising an anti-CD16 antibody and a cytokine IL15; preferably, the anti-CD16 antibody is Fab, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody or nanobody; more preferably, the CD16 antibody is a nanobody.
9. The fusion protein according to claim 8, characterized in that The fusion protein comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; Preferably, the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; More preferably, the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; Preferably, the fusion protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:30; More preferably, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:29 or SEQ ID NO:
30.
10. The fusion protein according to claim 8 or 9, characterized in that: The fusion protein also comprises a chimeric antigen receptor.
11. The fusion protein according to any one of claims 8 to 10, characterized in that: The fusion protein comprising the anti-CD16 antibody and the cytokine IL15 is connected to the chimeric antigen receptor via a self-cleaving peptide; optionally, the self-cleaving peptide is P2A or T2A; Preferably, the self-cleaving peptide P2A comprises the amino acid sequence shown in SEQ ID NO: 23, and / or The self-cleaving peptide T2A comprises the amino acid sequence shown in SEQ ID NO:
24.
12. The fusion protein according to any one of claims 10 to 11, characterized in that The chimeric antigen receptor is capable of binding to one or more tumor-associated antigens; optionally, the tumor-associated antigens include CD19, CD22, CD33, CD70, DLL3, MSLN, EGFR, HER2, EPCAM, IL13Rα2, EphA2, PSMA, MAGE, MUC16, Claudin6, Claudin18.2, SSTR2, BCMA and / or GPRC5D.
13. The fusion protein according to any one of claims 10 to 12, characterized in that: The chimeric antigen receptor comprises a tumor-associated antigen binding molecule; preferably, the tumor-associated antigen binding molecule comprises Fab, F(ab')2, Fab', Fab'-SH, Fd, Fv, scFv, diabody or nanobody; more preferably, the tumor-associated antigen binding molecule comprises a nanobody or scFv.
14. The fusion protein according to any one of claims 10 to 13, characterized in that: The chimeric antigen receptor further comprises a signal peptide, a transmembrane region, a hinge region, an intracellular region, a signal domain, and a connecting peptide; Optionally, the signal peptide includes CD8α, GM-CSF signal peptide; The connecting peptide includes connecting peptide 1; The transmembrane region includes CD3, CD8, CD8α, CD28, NKG2D, or 2B4 transmembrane region; The hinge region includes a CD8 hinge region, a CD8α hinge region or a CD28 hinge region; The intracellular region includes CD28, ICOS, 4-1BB, OX40, CD27, or 2B4 intracellular region; The signaling domain comprises a CD3ζ signaling domain; Preferably, the chimeric antigen receptor comprises: a CD8α signal peptide, a connecting peptide 1, a NKG2D transmembrane region or a CD8α transmembrane region, a CD8 hinge region or a CD8α hinge region, a 2B4 intracellular region or a CD28 intracellular region, a CD3ζ signaling domain, or a combination thereof; More preferably, the CD8α signal peptide comprises the amino acid sequence shown in SEQ ID NO: 18; The connecting peptide 1 comprises the amino acid sequence shown in SEQ ID NO: 27; The NKG2D transmembrane region comprises the amino acid sequence shown in SEQ ID NO: 20; The CD8α transmembrane region comprises the amino acid sequence shown in SEQ ID NO:34; The CD8 hinge region comprises the amino acid sequence shown in SEQ ID NO: 19; The CD8α hinge region comprises the amino acid sequence shown in SEQ ID NO: 33; The 2B4 intracellular region comprises the amino acid sequence shown in SEQ ID NO: 21; The CD28 intracellular region comprises the amino acid sequence shown in SEQ ID NO:35; The CD3ζ signaling domain comprises the amino acid sequence shown in SEQ ID NO:
22.
15. The fusion protein according to any one of claims 10 to 14, characterized in that: The tumor-associated antigen is BCMA, GPRC5D, and / or CD19; optionally, the tumor-associated antigen binding molecule includes anti-BCMA nanoantibody, anti-GPRC5D nanoantibody, and / or anti-CD19 single-chain antibody.
16. The fusion protein according to claim 15, characterized in that (1) the anti-BCMA Nanobody comprises all three CDRs of the amino acid sequence shown in SEQ ID NO: 2, and the CDRs are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system; and / or (2) the anti-GPRC5D Nanobody comprises all three CDRs of the amino acid sequence shown in SEQ ID NO: 10, and the CDRs are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system; and or (3) the anti-CD19 single-chain antibody comprises all six CDRs of the amino acid sequence shown in SEQ ID NO:39, wherein the CDRs are determined according to the Kabat numbering system, the Chothia numbering system or the IMGT numbering system; Preferably, (1) determined by the Kabat numbering system, the three CDRs of the anti-BCMA nanobody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 6, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 7, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 8; and / or (2) Determined by the IMGT numbering system, the three CDRs of the anti-GPRC5D Nanobody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO: 11, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 12, and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 13; and / or (3) The anti-CD19 single-chain antibody comprises a heavy chain variable region VH and a light chain variable region VL. Determined by the Kabat numbering system, the three CDRs on the VH of the anti-CD19 single-chain antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO:40, CDR2 comprising the amino acid sequence shown in SEQ ID NO:41, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:42; the three CDRs on the VL of the anti-CD19 single-chain antibody are: CDR1 comprising the amino acid sequence shown in SEQ ID NO:43, CDR2 comprising the amino acid sequence shown in SEQ ID NO:44, and CDR3 comprising the amino acid sequence shown in SEQ ID NO:
45.
17. The fusion protein according to any one of claims 15 to 16, characterized in that: (1) The anti-BCMA nanobody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 2; Preferably, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 2; More preferably, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 2; Preferably, the anti-BCMA Nanobody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 2; More preferably, the anti-BCMA nanobody comprises the amino acid sequence shown in SEQ ID NO: 2; and / or (2) the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 10; Preferably, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 10; More preferably, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 10; Preferably, the anti-GPRC5D Nanobody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 10; More preferably, the anti-GPRC5D Nanobody comprises the amino acid sequence shown in SEQ ID NO: 10; and / or (3) the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO: 39; Preferably, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO: 39; More preferably, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO: 39; Preferably, the anti-CD19 single-chain antibody comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO: 39; More preferably, the anti-CD19 single-chain antibody comprises the amino acid sequence shown in SEQ ID NO:
39.
18. The cell according to any one of claims 1 to 7, or the fusion protein according to any one of claims 8 to 17, characterized in that: The anti-CD16 antibody is loaded monovalently or bivalently.
19. The fusion protein according to any one of claims 10 to 18, characterized in that: The fusion protein comprises an amino acid sequence having at least 90% identity to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38; Preferably, the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38; More preferably, the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38; Preferably, the fusion protein comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% identical to the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:38, respectively; More preferably, the fusion protein comprises the amino acid sequence shown in SEQ ID NO:32 or SEQ ID NO:
38.
20. The fusion protein according to any one of claims 8 to 19, characterized in that: The fusion protein can be expressed by the cell according to any one of claims 1 to 7.
21. An isolated nucleic acid, characterized in that The nucleic acid encodes the fusion protein according to any one of claims 8 to 20; optionally, the nucleic acid is a single-stranded nucleic acid or a double-stranded nucleic acid; preferably, the nucleic acid comprises a linear nucleic acid or a circular nucleic acid; preferably, the nucleic acid comprises DNA and RNA; preferably, the RNA is self-replicating or non-self-replicating.
22. A cell, characterized in that The cell expresses the fusion protein of any one of claims 10 to 20 or the nucleic acid of claim 21.
23. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the cell according to any one of claims 1-7 and 22, or the fusion protein according to any one of claims 8-20, or the nucleic acid according to claim 21; optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
24. Use of the cell according to any one of claims 1-7, 22, or the fusion protein according to any one of claims 8-20, or the nucleic acid according to claim 21, or the pharmaceutical composition according to claim 23 in the preparation of a medicament for treating a tumor in a subject in need thereof.
Citation Information
Cited By
Enhanced immune cell and use thereof
WO2026208966A1
